| program | Indication | Country | Discovery | Pre-clinical | Phase I | Phase II | Phase III | BLA |
|---|---|---|---|---|---|---|---|---|
| LP-003 (new generation of anti-IgE antibody) | Allergic rhinitis (AR) |  |
|
|||||
| Chronic spontaneity urticaria (CSU) | |
|
||||||
| Asthma | |
|
||||||
| Chronic rhinosinusitis with nasal polyps (CRSwNP) | |
|
||||||
| Asthma COPD overlapped (ACO) | - |
|
||||||
| LP-007 (new generation of anti-IL-5 antibody) | Asthma | - |
|
|||||
| Eosinophilic disease | - |
|
||||||
| New target (undisclosed bi-specific antibody) | Asthma | - |
|
|||||
| COPD | - |
|
| program | Indication | Country | Discovery | Pre-clinical | Phase I | Phase II | Phase III | BLA |
|---|---|---|---|---|---|---|---|---|
| LP-005 (C3 x C5 bi-functional antibody) | Paroxysmal nocturnal hemoglobinuria (PNH) | |
|
|||||
| IgA nephropathy (IgAN) | |
|
||||||
| Lupus nephropathy (LN) | |
|
||||||
| C3 glomerulopathy (C3G) | |
|
||||||
| amyotrophic lateral sclerosis (ALS) | - |
|
||||||
| Generalized myasthenia gravis (gMG) | - |
|
||||||
| Myelin-associated glycoprotein associated neuropathies (MAG-PN) | - |
|
||||||
| LP-006 (anti-fD antibody) | IgAN | - |
|
|||||
| LP-008 (AAV-based complement inhibitor) | Dry AMD | - |
|
| program | Indication | Country | Discovery | Pre-clinical | Phase I | Phase II | Phase III | BLA |
|---|---|---|---|---|---|---|---|---|
| LP-001 (long-acting EPO-Fc) | Myelodysplastic syndrome (MDS) | |
|
|||||
| Chronic kidney disease anemia (CKD Anemia) | |
|
||||||
| LP-002(long-acting growth hormone-Fc) Q2W-Q4W | Growth hormone deficiency (GHD) | - |
|
|||||
| LP-009 (long-acting coagulation factor VIII-Fc) Q1W-Q2W SC | Hemophilia A | - |
|
来源： Humbert M，Bousket J，Bachert C，et al.IgE介导的过敏性哮喘多重疾病和Omalizumab治疗的潜力[J].《过敏和临床免疫学杂志》，2019年，7（5）。DOI：10.1016/j.jaip.2019.02.030。
来源：古尔德·H·J，布莱恩·Y·C。IgE曲目与免疫学记忆：室间隔调节与抗体功能[J]。国际免疫学，2018（9）： 9。DOI：10.1093/nerm/dxy048。
| Items | LP-003 | Omalizumab | Ligelizumab |
|---|---|---|---|
| KD* Affinity to IgE | 2.08 pM | 1790 pM | 12.1 pM[a] |
| FcεRI bioassay | ++++ | ++ | +++ |
| FcεRI bioassay | ++++ | ++ | +++ |
| T 1/2 (healthy volunteers) | Q45~75 days | 17~20 days[b] | ~20 days[c] |
| FcεRI bioassay | ++++ | ++ | +++ |
| program | Indication | Country | Discovery | Pre-clinical | Phase I | Phase II | Phase III | BLA |
|---|---|---|---|---|---|---|---|---|
| LP-003 (new generation of anti-IgE antibody) | Allergic rhinitis (AR) | |
|
|||||
| Chronic spontaneity urticaria (CSU) | |
|
||||||
| Asthma | |
|
||||||
| Chronic rhinosinusitis with nasal polyps (CRSwNP) | |
|
||||||
| Asthma COPD overlapped (ACO) | - |
|
来源：Posch W， Bermejo-Jambrina M，Lass-Flrl C等。补体受体（CRs）在DC抗HIV-1免疫中的作用[J].免疫学前沿，2020,11。DOI：10.3389/fimmu.2020.572114…
来源：https://www.theisn.org/initiatives/toolkits/complement-mediated-kidney-disease-toolkit/#Overview-Complement
| Items | LP-005 | Eculizumab | Ravulizumab | Pegcetacoplan APL-2 | KP-104 | MASP-2 OMS721 |
|---|---|---|---|---|---|---|
| Target C5 | Yes | Yes | Yes | N/A | Yes | N/A |
| Target C3 | Yes | N/A | N/A | Yes | Yes | N/A |
| CP bioassay | ++++ | +++ | +++ | ++ | +++ | N/A |
| CP bioassay | ++++ | +++ | +++ | ++ | +++ | N/A |
| CP bioassay | ++++ | +++ | +++ | ++ | +++ | N/A |
| program | Indication | Country | Discovery | Pre-clinical | Phase I | Phase II | Phase III | BLA |
|---|---|---|---|---|---|---|---|---|
| LP-003 (new generation of anti-IgE antibody) | Allergic rhinitis (AR) | |
|
|||||
| Chronic spontaneity urticaria (CSU) | |
|
||||||
| Asthma | |
|
||||||
| Chronic rhinosinusitis with nasal polyps (CRSwNP) | |
|
||||||
| Asthma COPD overlapped (ACO) | - |
|
